Takeda Collaborates with Skyhawk Therapeutics to Develop RNA Splicing Modifiers for Neurodegenerative Diseases


  • Skyhawk to receive upfront, milestones & royalties on sales and will discover & preclinically develop targeted therapies utilizing its SkySTAR technology. Takeda to get an exclusive WW license to develop & commercialize targeted therapies for multiple neurodegenerative diseases
  • The focus of the agreement is to develop therapies directing central nervous system for improvement of targeted neurological disorders
  • Skyhawk’s SkySTAR technology involves RNA splicing, correcting the RNA expression in small molecule for neurological diseases

Click here to read full press release/ article | Ref: PRNewswire | Image: Biopharma-Reporter